EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis

Mairedan Muhetarijiang, Pengwei Zhu, Han Zhang, Xiangjie Sun, Yakui Wu, Qianwen Xu, Ryan Justin, Chenxi Li, Dongchen Zhou, Biqi Zhang, Jun Liu, Xiaosheng Hu und 1 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04188-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Mairedan Muhetarijiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Chemokine CXCL12, Neovascularization, Pathologic, Programmed Cell Death 1 Receptor. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Provincial Medical and Health Science and Technology Project, China, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs), particularly programmed cell death protein 1 (PD-1) blockades, have redefined oncology in the last decade. Previous studies on PD-1 blockades mostly concentrate on their interactions with immune cells. This study aims to investigate how PD-1 blockades affect endothelial cell (EC) heterogeneity in the tumor microenvironment (TME) and to explore potential targets for enhancing the anti-tumor effects of PD-1 blockades. Here, we established a pan-cancer EC atlas from the public database and revealed that PD-1 blockades repress the angiogenic population in ECs and inhibit the CXCL12-CXCR4 signaling derived from ECs. Using a murine tumor model built with Lewis Lung Carcinoma cell line, we further validated our findings that a PD-1 blockade, as well as a CXCR4 antagonist AMD3100, inhibited EC population in tumors and their CXCL12 expression. In addition, the combo therapy of the PD-1 blockade and AMD3100 showed superior anti-tumor effects to monotherapy. Moreover, we predicted MYC to be the potential regulator through which PD-1 blockades affect ECs. Together, our results suggest that PD-1 blockades have an anti-angiogenic effect besides boosting T cell immunity, and the CXCL12/CXCR4 pathway is a potential target for enhancing the effectiveness of PD-1 blockades.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Chemokine CXCL12Neovascularization, PathologicProgrammed Cell Death 1 ReceptorEndothelial CellsImmune Checkpoint InhibitorsNeoplasmsAnimalsMiceHumansSingle-Cell AnalysisBenzylaminesTumor MicroenvironmentMice, Inbred C57BLCyclamsSignal TransductionCarcinoma, Lewis LungCell Line, TumorAngiogenesis

Stichwörter der Autor:innen

CXCL12/CXCR4Endothelial cellIntegrated single-cell analysisPD-1 blockades

Substanzen

Receptors, CXCR4Chemokine CXCL12Programmed Cell Death 1 ReceptorBenzylaminesCXCR4 protein, humanCyclamsImmune Checkpoint InhibitorsplerixaforCXCL12 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • School of Medicine, Zhejiang University, Hangzhou, China.
  • Jinhua People's Hospital, Jinhua, China.
  • Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. 1196017@zju.edu.cn.
  • Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. ct010151452@zju.edu.cn.
  • Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, Affiliated First Hospital of Ningbo University, Ningbo, China. ct010151452@zju.edu.cn.

Förderung

  • Zhejiang Provincial Medical and Health Science and Technology Project, China
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Project of Medical Science Research Foundation from the Health Department of Zhejiang Province, China

Zitieren

APA

Muhetarijiang, M., Zhu, P., Zhang, H., Sun, X., Wu, Y., Xu, Q., Justin, R., Li, C., Zhou, D., Zhang, B., Liu, J., Hu, X., & Chen, T. (2025). A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04188-9

Vancouver

Muhetarijiang M, Zhu P, Zhang H, Sun X, Wu Y, Xu Q, et al. A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04188-9

BibTeX
@article{Muhetarijiang2025,
  author = {Muhetarijiang, Mairedan and Zhu, Pengwei and Zhang, Han and Sun, Xiangjie and Wu, Yakui and Xu, Qianwen and Justin, Ryan and Li, Chenxi and Zhou, Dongchen and Zhang, Biqi and Liu, Jun and Hu, Xiaosheng and Chen, Ting},
  title = {A pan-cancer single-cell analysis reveals the effect of PD-1 blockades on tumor angiogenesis by inhibiting the endothelial CXCL12-CXCR4 axis},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04188-9}
}
Kostenlos starten →